These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 9491325)

  • 1. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer.
    Jenkins R; Takahashi S; DeLacey K; Bergstralh E; Lieber M
    Genes Chromosomes Cancer; 1998 Feb; 21(2):131-43. PubMed ID: 9491325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
    Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
    Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression.
    Takahashi S; Shan AL; Ritland SR; Delacey KA; Bostwick DG; Lieber MM; Thibodeau SN; Jenkins RB
    Cancer Res; 1995 Sep; 55(18):4114-9. PubMed ID: 7664288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
    Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
    Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.
    Takahashi S; Alcaraz A; Brown JA; Borell TJ; Herath JF; Bergstralh EJ; Lieber MM; Jenkins RB
    Clin Cancer Res; 1996 Jan; 2(1):137-45. PubMed ID: 9816100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer.
    Latil A; Cussenot O; Fournier G; Baron JC; Lidereau R
    Clin Cancer Res; 1995 Nov; 1(11):1385-9. PubMed ID: 9815935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular cytogenetic analysis of 7q31 in prostate cancer.
    Jenkins RB; Qian J; Lee HK; Huang H; Hirasawa K; Bostwick DG; Proffitt J; Wilber K; Lieber MM; Liu W; Smith DI
    Cancer Res; 1998 Feb; 58(4):759-66. PubMed ID: 9485032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma.
    Cunningham JM; Shan A; Wick MJ; McDonnell SK; Schaid DJ; Tester DJ; Qian J; Takahashi S; Jenkins RB; Bostwick DG; Thibodeau SN
    Cancer Res; 1996 Oct; 56(19):4475-82. PubMed ID: 8813143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer.
    Kawana Y; Ichikawa T; Suzuki H; Ueda T; Komiya A; Ichikawa Y; Furuya Y; Akakura K; Igarashi T; Ito H
    Prostate; 2002 Sep; 53(1):60-4. PubMed ID: 12210480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.
    Valeri A; Fromont G; Sakr W; Azzouzi R; Dey J; Chantrel-Groussard K; Latil A; Berthon P; Cussenot O; Pontes JE; Cher ML
    Urol Oncol; 2005; 23(2):87-92. PubMed ID: 15869992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer.
    Matsuyama H; Pan Y; Yoshihiro S; Kudren D; Naito K; Bergerheim US; Ekman P
    Prostate; 2003 Feb; 54(2):103-11. PubMed ID: 12497583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma.
    Kitamura Y; Shimizu K; Tanaka S; Ito K; Emi M
    Clin Cancer Res; 2000 May; 6(5):1819-25. PubMed ID: 10815903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
    Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
    Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential chromosome allelic imbalance in the progression of human prostate cancer.
    Latil A; Fournier G; Cussenot O; Lidereau R
    J Urol; 1996 Dec; 156(6):2079-83. PubMed ID: 8911394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frequent allelic losses in tumor-associated stromal cells and tumor epitelium of prostate cancer].
    Kekeeva TV; Popova OP; Shegaĭ PV; Zavalishina LE; Andreeva IuIu; Zaletaev DV; Nemtsova MV
    Mol Biol (Mosk); 2008; 42(1):96-101. PubMed ID: 18389625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
    Strohmeyer DM; Berger AP; Moore DH; Bartsch G; Klocker H; Carroll PR; Loening SA; Jensen RH
    Prostate; 2004 Apr; 59(1):43-58. PubMed ID: 14991865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic imbalance and biochemical outcome after radical prostatectomy.
    Bott SR; Masters JR; Parkinson MC; Kirby RS; Feneley M; Hooper J; Williamson M
    Prostate Cancer Prostatic Dis; 2006; 9(2):160-8. PubMed ID: 16534511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
    Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
    Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
    Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
    Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.